JP2001511797A - 創傷の治癒 - Google Patents
創傷の治癒Info
- Publication number
- JP2001511797A JP2001511797A JP53544198A JP53544198A JP2001511797A JP 2001511797 A JP2001511797 A JP 2001511797A JP 53544198 A JP53544198 A JP 53544198A JP 53544198 A JP53544198 A JP 53544198A JP 2001511797 A JP2001511797 A JP 2001511797A
- Authority
- JP
- Japan
- Prior art keywords
- lap
- healing
- tgf
- peptide
- wound healing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000029663 wound healing Effects 0.000 title claims abstract description 44
- 206010052428 Wound Diseases 0.000 claims abstract description 85
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 84
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 48
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 48
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 27
- 108020004414 DNA Proteins 0.000 claims description 20
- 230000035876 healing Effects 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 102000053602 DNA Human genes 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 7
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims description 6
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000036269 ulceration Effects 0.000 claims description 5
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 208000028389 Nerve injury Diseases 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 3
- 230000008764 nerve damage Effects 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 229940072041 transforming growth factor beta 2 Drugs 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
- 102400000401 Latency-associated peptide Human genes 0.000 description 94
- 101800001155 Latency-associated peptide Proteins 0.000 description 94
- 230000000694 effects Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 239000013598 vector Substances 0.000 description 12
- 230000036573 scar formation Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 8
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 206010016654 Fibrosis Diseases 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 230000004761 fibrosis Effects 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108091005735 TGF-beta receptors Proteins 0.000 description 5
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 3
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 2
- 102000008121 Latent TGF-beta Binding Proteins Human genes 0.000 description 2
- 108010049807 Latent TGF-beta Binding Proteins Proteins 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- -1 TGF-β1-5 Proteins 0.000 description 2
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 description 2
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000037309 reepithelialization Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000038460 IGF Type 2 Receptor Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.創傷治癒速度を増加する医薬の製造のための潜在性関連ペプチドまたはそ の機能的類縁体の使用。 2.潜在性関連ペプチドまたはその機能的類縁体が、トランスフォーミング成 長因子βを潜在状態に維持する能力を有する請求項1に記載の使用。 3.潜在性関連ペプチドまたはその機能的類縁体が、トランスフォーミング成 長因子β1またはトランスフォーミング成長因子β2を潜在状態に維持する能力 を有する請求2に記載の使用。 4.医薬が、急性創傷の治癒速度を増加するためのものである前記請求項のい ずれかに記載の使用。 5.急性創傷が、刺し傷、火傷、電気的外科手術の結果生じる神経損傷または 内臓の創傷のいずれか一つである、請求項4に記載の使用。 6.医薬が慢性創傷の治癒速度を増加するためのものである請求項1〜3のい ずれかひとつに記載の使用。 7.慢性創傷が、糖尿病性潰瘍形成、静脈潰瘍形成および床ずれ潰瘍形成のい ずれか一つである、請求項6に記載の使用。 8.医薬が、治癒が困難となっている個体の創傷治癒速度を増加するためのも のである前記請求項のいずれかに記載の使用。 9.治癒が困難となっている個体が、老年のヒトまたは動物である請求項8に 記載の使用。 10.液剤、軟膏、クリーム剤、ゲル剤、ヒドロゲル剤、粉剤、エアロゾル剤 またはインプラントの形体である前記請求項のいずれかに記載の使用。 11.局所適用のための前記請求項のいずれかに記載の使用。 12.医薬が、潜在性関連ペプチドまたはその機能的類縁体を1ng〜10m g含有する前記請求項のいずれかに記載の使用。 13.潜在性関連ペプチドまたはそのタンパク質類縁体が使用され、該ペプチ ドまたは類縁体が、トランスフォーミング成長因子β発現組織、培養物中で成長 したトランスフォーミング成長因子β発現細胞、該ペプチドまたは類縁体を発現 するように遺伝子工作された細胞あるいは該ペプチドまたは類縁体を発現するよ うに遺伝子工作されたトランスジェニック動物から得られる前記請求項のいずれ かに記載の使用。 14.潜在性関連ペプチドの機能的類縁体が使用され、該ペプチドが化学的ま たは遺伝子工作的に修飾された潜在性関連ペプチドまたは化学的に合成された化 合物である請求項1〜12のいずれかひとつに記載の使用。 15.治療上有効量の潜在性ペプチドまたはその機能的類縁体を創傷の部位へ 適用することを特徴とする創傷治癒の速度を増加する方法。 16.治療上有効量の潜在性ペプチドまたはその機能的類縁体および医薬的に 許容しうる担体を含む、創傷治癒の速度を増加するための組成物。 17.液剤、軟膏、クリーム剤、ゲル剤、ヒドロゲル剤、粉剤、エアロゾル剤 またはインプラントの形体である請求項16に記載の組成物。 18.遺伝子療法技術に使用するためのデリバリーシステムであって、創傷の 治癒を調節する潜在性関連ペプチドまたはその機能的類縁体をコードするDNA 分子を特徴とし、該DNA分子が、転写されて該ペプチドまたは類縁体を発現す る能力を有する分子である、デリバリーシステム。 19.創傷治癒の速度を増加する医薬の製造のための請求項18に記載のデリ バリーシステムの使用。 20.治療を必要とする患者に、治療上有効量の請求項18に記載のデリバリ ーシステムを投与することを特徴とする創傷治癒の速度を増加する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9702943.3A GB9702943D0 (en) | 1997-02-13 | 1997-02-13 | Wound healing |
GB9702943.3 | 1997-02-13 | ||
PCT/GB1998/000316 WO1998035695A1 (en) | 1997-02-13 | 1998-02-13 | Wound healing |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001511797A true JP2001511797A (ja) | 2001-08-14 |
JP2001511797A5 JP2001511797A5 (ja) | 2005-09-08 |
JP4307561B2 JP4307561B2 (ja) | 2009-08-05 |
Family
ID=10807557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53544198A Expired - Fee Related JP4307561B2 (ja) | 1997-02-13 | 1998-02-13 | 創傷の治癒 |
Country Status (13)
Country | Link |
---|---|
US (1) | US6319907B1 (ja) |
EP (1) | EP1009425B1 (ja) |
JP (1) | JP4307561B2 (ja) |
AT (1) | ATE223228T1 (ja) |
AU (1) | AU728851B2 (ja) |
CA (1) | CA2280873C (ja) |
DE (1) | DE69807710T2 (ja) |
DK (1) | DK1009425T3 (ja) |
ES (1) | ES2181165T3 (ja) |
GB (1) | GB9702943D0 (ja) |
HK (1) | HK1025504A1 (ja) |
PT (1) | PT1009425E (ja) |
WO (1) | WO1998035695A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6756060B1 (en) * | 1996-09-19 | 2004-06-29 | Usbiomaterials Corp. | Anti-inflammatory and antimicrobial uses for bioactive glass compositions |
WO2001096527A2 (en) * | 2000-06-14 | 2001-12-20 | Chanda Zaveri | Peptides with physiological activity |
US20100129332A1 (en) * | 2000-07-31 | 2010-05-27 | Tamar Tennenbaum | Methods and pharmaceutical compositions for healing wounds |
US20030148924A1 (en) * | 2002-07-09 | 2003-08-07 | Tamar Tennenbaum | Methods and pharmaceutical compositions of healing wounds |
US20040037828A1 (en) * | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
AU2001284364B2 (en) * | 2000-07-31 | 2006-09-28 | Bar Ilan University | Methods and pharmaceutical compositions for healing wounds |
US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
WO2005016254A2 (en) * | 2003-07-16 | 2005-02-24 | The Ohio State University Research Foundation | Methods and reagents for treating inflammation and fibrosis |
WO2005013885A2 (en) * | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
WO2007026356A2 (en) * | 2005-08-29 | 2007-03-08 | Healor Ltd. | Methods and compositions for prevention and treatment of diabetic and aged skin |
KR20100027091A (ko) | 2006-11-15 | 2010-03-10 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
KR20100040912A (ko) * | 2007-07-30 | 2010-04-21 | 힐로 리미티드 | 약제학적 조성물 및 관련 방법 |
CN101855235B (zh) * | 2007-10-29 | 2013-04-24 | 赫里克斯生物医疗公司 | 保护性皮肤护理四肽 |
EP2252690A2 (en) * | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars |
WO2009085269A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions |
CA2710386A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Improved medical devices |
US20100172217A1 (en) * | 2009-01-08 | 2010-07-08 | Von Bezold Ernst | System of Methods and Apparati for Handling and Modifying Information Energy and Matter by Formative Resonance |
KR20130095835A (ko) * | 2009-02-24 | 2013-08-28 | 힐로 리미티드 | 여드름 및 기타 질환 치료용 비스파틴 치료제 |
WO2011083483A2 (en) | 2010-01-11 | 2011-07-14 | Healor Ltd. | Method for treatment of inflammatory disease and disorder |
US9387183B2 (en) | 2011-12-28 | 2016-07-12 | Kuwait University | Method of treating diabetes-related impaired wound healing |
EP3183346A4 (en) | 2014-08-22 | 2018-10-24 | Auckland Uniservices Limited | Channel modulators |
US10232009B1 (en) * | 2017-09-29 | 2019-03-19 | Pro Sunfun Biotech Research And Development Co., Ltd. | Peptide for promoting wound healing, its composition and method of using the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2068204C (en) * | 1989-11-22 | 2002-02-12 | Arthur Levinson | Latency associated peptides and uses therefor |
GB9106678D0 (en) | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
AU5587094A (en) * | 1992-10-26 | 1994-05-24 | Kirin Brewery Company, Limited | Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide |
US6074840A (en) * | 1994-02-18 | 2000-06-13 | The Regents Of The University Of Michigan | Recombinant production of latent TGF-beta binding protein-3 (LTBP-3) |
EP0754058B1 (en) * | 1994-03-29 | 1999-11-03 | The Victoria University Of Manchester | Wound healing |
-
1997
- 1997-02-13 GB GBGB9702943.3A patent/GB9702943D0/en active Pending
-
1998
- 1998-02-13 US US09/367,262 patent/US6319907B1/en not_active Expired - Fee Related
- 1998-02-13 CA CA2280873A patent/CA2280873C/en not_active Expired - Fee Related
- 1998-02-13 JP JP53544198A patent/JP4307561B2/ja not_active Expired - Fee Related
- 1998-02-13 ES ES98903122T patent/ES2181165T3/es not_active Expired - Lifetime
- 1998-02-13 EP EP98903122A patent/EP1009425B1/en not_active Expired - Lifetime
- 1998-02-13 WO PCT/GB1998/000316 patent/WO1998035695A1/en active IP Right Grant
- 1998-02-13 PT PT98903122T patent/PT1009425E/pt unknown
- 1998-02-13 AU AU59953/98A patent/AU728851B2/en not_active Ceased
- 1998-02-13 DK DK98903122T patent/DK1009425T3/da active
- 1998-02-13 DE DE69807710T patent/DE69807710T2/de not_active Expired - Lifetime
- 1998-02-13 AT AT98903122T patent/ATE223228T1/de active
-
2000
- 2000-06-22 HK HK00103783A patent/HK1025504A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69807710T2 (de) | 2003-06-05 |
EP1009425A1 (en) | 2000-06-21 |
CA2280873C (en) | 2010-04-06 |
PT1009425E (pt) | 2002-11-29 |
WO1998035695A1 (en) | 1998-08-20 |
HK1025504A1 (en) | 2000-11-17 |
AU728851B2 (en) | 2001-01-18 |
DE69807710D1 (de) | 2002-10-10 |
US6319907B1 (en) | 2001-11-20 |
JP4307561B2 (ja) | 2009-08-05 |
ATE223228T1 (de) | 2002-09-15 |
EP1009425B1 (en) | 2002-09-04 |
CA2280873A1 (en) | 1998-08-20 |
AU5995398A (en) | 1998-09-08 |
DK1009425T3 (da) | 2002-10-14 |
ES2181165T3 (es) | 2003-02-16 |
GB9702943D0 (en) | 1997-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4307561B2 (ja) | 創傷の治癒 | |
JP3919212B2 (ja) | 線維障害の創傷治療処置 | |
AU2006268091B2 (en) | Promotion of epithelial regeneration | |
US7566446B2 (en) | Wound healing and treatment of fibrosis | |
JP2012211185A (ja) | 創傷治癒のためのil−10関連ペプチド | |
WO1998036061A2 (en) | Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity | |
US20110059896A1 (en) | Use of furin convertase inhibitors in the treatment of fibrosis and scarring | |
EP0855916B1 (en) | Pharmaceutical composition containing an activin stimulator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050121 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080318 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080618 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080618 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081031 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090407 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090430 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120515 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |